INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION
ABSTRACT Objective: To identify whether the use of prophylactic intrasite vancomycin as an adjuvant is a protective factor against deep tissue infection of the surgical site. Methods: Retrospective, descriptive, case-control study evaluating 210 patients, of whom 70 received intrasite vancomycin...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Sociedade Brasileira de Coluna (SBC)
2016-03-01
|
Series: | Coluna/Columna |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-18512016000100044&lng=en&tlng=en |
id |
doaj-612f455491b04499bdda294b203b6e56 |
---|---|
record_format |
Article |
spelling |
doaj-612f455491b04499bdda294b203b6e562020-11-25T00:21:09ZengSociedade Brasileira de Coluna (SBC)Coluna/Columna 2177-014X2016-03-01151444710.1590/S1808-185120161501154501S1808-18512016000100044INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSIONJorge Álvaro González RossAlfredo Javier Moheno GallardoEulalio Elizalde MartínezJosé Manuel Pérez AtanasioRuth Martínez MartínezABSTRACT Objective: To identify whether the use of prophylactic intrasite vancomycin as an adjuvant is a protective factor against deep tissue infection of the surgical site. Methods: Retrospective, descriptive, case-control study evaluating 210 patients, of whom 70 received intrasite vancomycin (case group) and 140 were controls. It was made a follow up for at least one year, reviewing the physical and electronic records. Data were tabulated in spreadsheets (Excel) including all variables and the statistical analysis was made with Epi InfoTM 7 to calculate the odds ratio. Results: Seven cases of deep infection occurred in the control group and none was found in the case group (odds ratio [95% confidence interval]: 0.1262 [0.007-2.24], P = 0.1585). Among the predisposing factors, diabetes and surgical time were the most relevant. Conclusions: Intrasite use of vancomycin has a protective effect against deep infection in patients undergoing lumbar fusion surgery without presenting considerable side effects.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-18512016000100044&lng=en&tlng=enVancomicinaFusión vertebralInfección de herida operatoriaProfilaxis antibiótica |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jorge Álvaro González Ross Alfredo Javier Moheno Gallardo Eulalio Elizalde Martínez José Manuel Pérez Atanasio Ruth Martínez Martínez |
spellingShingle |
Jorge Álvaro González Ross Alfredo Javier Moheno Gallardo Eulalio Elizalde Martínez José Manuel Pérez Atanasio Ruth Martínez Martínez INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION Coluna/Columna Vancomicina Fusión vertebral Infección de herida operatoria Profilaxis antibiótica |
author_facet |
Jorge Álvaro González Ross Alfredo Javier Moheno Gallardo Eulalio Elizalde Martínez José Manuel Pérez Atanasio Ruth Martínez Martínez |
author_sort |
Jorge Álvaro González Ross |
title |
INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION |
title_short |
INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION |
title_full |
INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION |
title_fullStr |
INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION |
title_full_unstemmed |
INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION |
title_sort |
intrasite vancomycin powder as a prophylactic adjuvant in lumbar fusion |
publisher |
Sociedade Brasileira de Coluna (SBC) |
series |
Coluna/Columna |
issn |
2177-014X |
publishDate |
2016-03-01 |
description |
ABSTRACT Objective: To identify whether the use of prophylactic intrasite vancomycin as an adjuvant is a protective factor against deep tissue infection of the surgical site. Methods: Retrospective, descriptive, case-control study evaluating 210 patients, of whom 70 received intrasite vancomycin (case group) and 140 were controls. It was made a follow up for at least one year, reviewing the physical and electronic records. Data were tabulated in spreadsheets (Excel) including all variables and the statistical analysis was made with Epi InfoTM 7 to calculate the odds ratio. Results: Seven cases of deep infection occurred in the control group and none was found in the case group (odds ratio [95% confidence interval]: 0.1262 [0.007-2.24], P = 0.1585). Among the predisposing factors, diabetes and surgical time were the most relevant. Conclusions: Intrasite use of vancomycin has a protective effect against deep infection in patients undergoing lumbar fusion surgery without presenting considerable side effects. |
topic |
Vancomicina Fusión vertebral Infección de herida operatoria Profilaxis antibiótica |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-18512016000100044&lng=en&tlng=en |
work_keys_str_mv |
AT jorgealvarogonzalezross intrasitevancomycinpowderasaprophylacticadjuvantinlumbarfusion AT alfredojaviermohenogallardo intrasitevancomycinpowderasaprophylacticadjuvantinlumbarfusion AT eulalioelizaldemartinez intrasitevancomycinpowderasaprophylacticadjuvantinlumbarfusion AT josemanuelperezatanasio intrasitevancomycinpowderasaprophylacticadjuvantinlumbarfusion AT ruthmartinezmartinez intrasitevancomycinpowderasaprophylacticadjuvantinlumbarfusion |
_version_ |
1725363671963533312 |